Pangaea Oncology, S.A. (PANG.MC)

1,7800 -0,0800 (-4,30%) Al cierre: 12:00PM CEST

Pangaea Oncology, S.A.

Sabino Arana, 5-19
Barcelona 08028
Spain
34 93 409 79 81
https://www.panoncology.com

Sector(es): Healthcare
Sector: Diagnostics & Research
Empleados a tiempo completo: 58

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Javier Rivela-Rodriguez C.F.A., M.B.A.	Co-Founder, CEO & Director	N/A	N/A	N/A
Dr. Rafael Rosell Costa M.D., Ph.D.	Chief Scientific Officer, President & Member of Scientific Committee	N/A	N/A	N/A
Alejandro Garcia Moncayo M.B.A.	Executive Director of Corporate & CFO	N/A	N/A	N/A
Ms. Carmen Albiol	Head of Operations for IOR	N/A	N/A	N/A
Dr. Miguel Angel Molina B.Sc., Ph.D.	Executive Director of Research & Development and Member of Scientific Committee	N/A	N/A	N/A
Alejandro Martínez M.D.	Executive Director of Clinical Trials & Chief of Staff of Dexeus Hospital	N/A	N/A	N/A
Lluis Cirera M.D., Ph.D.	Chief of Staff of Hospital Universitario Sagrat Cor	N/A	N/A	N/A
Xavier Gonzalez M.D.	Chief of Staff of Hospital General de Catalunya	N/A	N/A	N/A
Juan Roldan M.D., Ph.D.	Chief of Staff of PECTUS	N/A	N/A	N/A
Jose Manuel Pere M.D., Ph.D.	Chief of Staff of IBCC, Teknon	N/A	N/A	N/A

Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. It also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2006 and is based in Barcelona, Spain.

Gobierno corporativo

El ISS Governance QualityScore de Pangaea Oncology, S.A., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.